Dr. LU Haiqi graduated from Zhejiang University School of Medicine in 2014 with a Ph.D. degree in oncology. Since the same year, she has worked in the Department of Medical Oncology in SRRSH and engaged in clinical practice, scientific research, and teaching of malignant tumor diagnosis and comprehensive treatment. She has served as a Key Sub-PI for over 40 domestic and international clinical studies related to new drugs for solid tumors, and has extensive clinical experience, especially in the diagnosis and precision treatment of different subtypes of breast malignancies, as well as in the research of drug resistance mechanisms, where she has some unique insights. From 2019 to 2020, she served as a visiting scholar at the Dana-Farber Cancer Institute of Harvard Medical School for scientific research training. She has been responsible for one project funded by the National Natural Science Foundation of China, one project funded by the Zhejiang Province Natural Science Foundation, and one general project from the Zhejiang Province Medical and Health Science and Technology Plan. She has also participated as the main researcher in 5 projects funded by the National Natural Science Foundation of China and 3 projects funded by the Zhejiang Province Natural Science Foundation. She has published 18 SCI papers in journals such as Autophagy, Cell Death & Disease, FEBS Letters, and BBA Reviews on Cancer.

Member of the Tumor Metastasis Committee, Zhejiang Anti-Cancer Association

Member of the Family Inherited Tumor Committee, Zhejiang Anti-Cancer Association

Member of the Tumor Cardiology Committee, Zhejiang Anti-Cancer Association

Deputy Secretary-General of the Youth Committee of the Tumor Precision Diagnosis and Treatment Committee, Zhejiang Anti-Cancer Association.